1. INTRODUCTION:

Uveitis, characterized by inflammation of the uveal tract of the eye (Figure 1), is a complex and potentially sight-threatening condition that poses significant challenges in its treatment. Current therapeutic approaches, including corticosteroids, immunomodulators, and biologics, often exhibit limited efficacy and may lead to systemic side effects when administered orally or intravenously. Hence, there is a pressing need for innovative drug delivery systems which can enhance the bioavailability of therapeutic agents while minimizing systemic exposure and ocular toxicity¹.

In recent years, drug delivery systems based on nanotechnology have attracted significant interest for their potential to enhance the treatment of ocular conditions, including uveitis. Among these approaches, nanomicellar formulations have stood out as a promising method for efficiently delivering drugs to ocular tissues².

Figure 1. Healthy eye and Uveitis infection

Nanomicelles are self-assembled colloidal nanoparticles composed of amphiphilic molecules, which can encapsulate hydrophobic drugs in their core and solubilize hydrophilic drugs in their shell, thereby enhancing their stability and bioavailability³.

Numerous studies have shown the effectiveness of nanomicellar-based drug delivery systems in enhancing ocular drug delivery and improving therapeutic outcomes in various eye diseases⁴. By utilizing the distinct characteristics of nanomicelles, including their small size, high drug-loading capacity, and sustained release capabilities, researchers have successfully achieved targeted and controlled drug delivery to inflamed ocular tissues in uveitis.

This review aims to deliver an extensive analysis of the development and application of nanomicellar-based topical drug delivery systems for uveitis treatment. It will discuss the current challenges in uveitis treatment, the advantages of nanomicelles as drug carriers, the pathophysiology of uveitis, and the mechanisms of action of nanomicelles in targeting inflammatory pathways. Furthermore, it will review the recent advancements in the formulation development, efficacy, and safety evaluation of nanomicellar-based drug delivery systems for uveitis.

2. Nanomicellar-Based Drug Delivery Systems:

Nanomicelles, colloidal nanoparticles formed by self-assembly of amphiphilic molecules in aqueous solution, possess unique properties ideal for drug delivery. They typically consist of a hydrophobic core surrounded by a hydrophilic shell, allowing for encapsulation of hydrophobic drugs within the core and solubilization of hydrophilic drugs in the shell (Figure 2)⁵.

Figure 2. Structure of Nanomicelle

2.1. Advantages of Nanomicelles for Topical Drug Delivery:

Nanomicelles offer several advantages for topical drug delivery, including improved stability, enhanced drug solubility, prolonged drug release, and targeted delivery to specific tissues. Their small size facilitates penetration through biological barriers, such as the ocular epithelium, allowing for efficient drug uptake and distribution within the target tissues⁶.

2.2. Role in Enhancing Ocular Drug Bioavailability:

In ocular drug delivery, nanomicelles have demonstrated significant potential in enhancing drug bioavailability and therapeutic efficacy. By encapsulating drugs within nanomicelles, their ocular retention time is prolonged, leading to sustained release and prolonged therapeutic effects. Additionally, nanomicelles can overcome limitations associated with conventional eye drops, such as low drug permeability and rapid clearance, thus improving drug penetration and distribution within ocular tissues⁷.

3. Pathophysiology of Uveitis:

Uveitis involves inflammation of the uveal tract, encompassing the ciliary body, iris and choroid. This condition affects normal functioning within the eye. Its pathophysiology involves intricate interactions among the immune system, genetic predispositions, and environmental factors, resulting in dysregulated immune responses and subsequent tissue damage within the eye⁸.

3.1. Immune Dysregulation:

Uveitis is primarily driven by dysregulated immune responses, involving both innate and adaptive immune mechanisms. Antigen- presenting cells, such as macrophages and dendritic cells, present ocular antigens to T-lymphocytes, triggering an inflammatory cascade. That can results in the recruitment of leukocytes, including neutrophils, monocytes and lymphocytes, to the site of inflammation, leading to tissue damage and vascular leakage.

3.2. Autoimmune Responses:

Uveitis is frequently linked to autoimmune disorders like ankylosing spondylitis, rheumatoid arthritis and inflammatory bowel disease. In these conditions, abnormal immune responses targeting self-antigens can result in the formation of immune complexes and the activation of pro-inflammatory cytokines that can contribute to ocular inflammation and tissue damage.

3.3. Genetic Predisposition:

Genetic factors play a significant role in the pathogenesis of uveitis, with certain HLA alleles and polymorphisms in immune-related genes implicated in disease susceptibility. These genetic variants can influence immune cell function, cytokine production, and antigen presentation, predisposing individuals to develop uveitis in response to environmental triggers.

3.4. Environmental Triggers:

Environmental factors, such as infections, trauma, and exposure to toxins, can trigger or exacerbate uveitis in genetically susceptible individuals. Infectious agents including parasites, bacteria and viruses, can directly invade ocular tissues or induce immune responses that contribute to inflammation. Traumatic injury to the eye can disrupt the blood-ocular barrier and trigger an inflammatory response, leading to uveitis. Understanding the underlying pathophysiology of uveitis is crucial for developing targeted therapeutic approaches that modulate immune responses, suppress inflammation, and preserve ocular integrity. By elucidating the mechanisms driving uveitis, researchers can identify novel drug targets and develop new treatment strategies to improve outcomes for patients with this sight-threatening condition.

4. Target Sites for Drug Delivery in Uveitis:

The effective treatment of uveitis necessitates targeted drug delivery to the specific ocular tissues involved in inflammation. Key target areas include the anterior segment (e.g., iris and ciliary body), posterior segment (e.g., retina and choroid), and the vitreous cavity (Figure 3). Drug delivery systems must bypass ocular barriers, such as the blood-retinal barrier and corneal epithelium, to attain therapeutic drug concentrations at these sites⁹.

Figure 3. Anatomy of Eye

Conventional treatment approaches for uveitis, such as corticosteroids, immunomodulators, and, biologics, are associated with several challenges, including limited efficacy, frequent dosing requirements, and systemic side effects. Corticosteroids, while effective in suppressing inflammation, may cause cataracts, glaucoma, and increased intraocular pressure with long-term use. Immunomodulators and biologics, while targeting specific immune pathways, may also lead to systemic immunosuppression and increased susceptibility to infections¹⁰.

5. Development of Nanomicellar Formulations for Uveitis Treatment:

Uveitis is a sight-threatening inflammatory condition affecting the eye, necessitating effective treatment strategies to mitigate inflammation and preserve vision. Nanomicellar formulations have emerged as promising carriers for ocular drug delivery due to their ability to improve drug solubility, enhance bioavailability, and target inflamed ocular tissues. The development of nanomicellar formulations for uveitis treatment involves several key stages:

5.1. Selection of Drug Candidates:

Selection of appropriate drug candidates is a crucial step in the development of nanomicellar formulations for uveitis treatment. The chosen drugs should possess therapeutic efficacy against uveitis-related inflammation while demonstrating favorable physicochemical properties for encapsulation within nanomicelles.

5.1.1. Anti-Inflammatory Agents:

It is preferred to use drug candidates with strong anti-inflammatory properties for treating uveitis. Corticosteroids, immunomodulatory drugs, and nonsteroidal anti-inflammatory drugs (NSAIDs) are often utilized to reduce eye inflammation and relieve uveitis symptoms.

5.1.2. Hydrophobicity:

Drugs with moderate to high hydrophobicity are ideal candidates for encapsulation within nanomicelles, as they can be effectively solubilized in the hydrophobic core of the micelles. Hydrophobic drugs tend to exhibit enhanced bioavailability and prolonged residence time in ocular tissues following nanomicellar delivery.

5.1.3. Therapeutic Potency:

The selected drug candidates should demonstrate potent therapeutic efficacy against uveitis at clinically relevant doses. High drug potency allows for lower drug concentrations in the nanomicellar formulation, minimizing the risk of ocular and systemic side effects.

5.1.4. Biocompatibility:

Drug candidates should exhibit excellent biocompatibility and safety profiles to minimize the risk of ocular irritation, cytotoxicity, and immunogenicity. Biocompatible drugs are well-tolerated by ocular tissues and are less likely to induce adverse reactions upon administration.

5.1.5. Stability:

The stability of drug candidates in solution and upon encapsulation within nanomicelles is crucial for maintaining therapeutic efficacy throughout the shelf life of the formulation. Drugs prone to degradation or chemical instability may require formulation optimization or stabilization techniques to ensure long- term stability^11-13. Overall, the selection of suitable drug candidates is a critical determinant of the success of nanomicellar formulations for uveitis treatment. By carefully evaluating the pharmacological properties and characteristics of potential drug candidates, researchers can identify promising candidates for further formulation development and preclinical evaluation.

5.2. Formulation Development Techniques:

Formulation development techniques play a crucial role in the successful design and fabrication of nanomicellar formulations for uveitis treatment. Several techniques are employed to optimize the physicochemical properties, drug loading capacity, stability, and biocompatibility of nanomicelles. Some commonly utilized formulation development techniques are shown in Table 1.

These formulation development techniques offer flexibility in tailoring the physicochemical properties and drug release characteristics of nanomicellar formulations for uveitis treatment. By optimizing these techniques, researchers can design nanomicelles with enhanced drug loading capacity, stability, and ocular bioavailability, ultimately improving therapeutic outcomes for uveitis patients ¹⁴.

5.3. Optimization of Formulation Parameters:

Optimizing formulation parameters is essential to develop effective nanomicellar formulations for uveitis treatment. Several critical parameters must be considered during the formulation process to ensure optimal drug loading, stability, ocular bioavailability, and therapeutic efficacy.

5.3.1. Nanomicelle Composition:

The composition of nanomicelles, including the type of surfactant, co-surfactant, and lipid components, significantly influences the physicochemical properties and performance of the formulation. Selection of appropriate excipients and their concentrations is crucial to achieve optimal drug solubilization, stability, and ocular penetration.

5.3.2. Drug Loading Capacity:

Optimization of drug loading capacity is essential to maximize the encapsulation efficiency and therapeutic payload of nanomicellar formulations. Various techniques, such as solvent evaporation, thin-film hydration, and dialysis, can be employed to enhance drug loading while maintaining the structural integrity and stability of nanomicelles.

5.3.3. Particle Size and Distribution:

The particle size and distribution of nanomicelles play a critical role in determining their ocular penetration, retention, and efficacy. Optimization of formulation parameters, such as surfactant concentration, stirring speed, and hydration temperature, can help achieve uniform particle size distribution and minimize aggregation.

5.3.4. Zeta Potential:

Zeta potential, a measure of the surface charge of nanomicelles, influences their stability, dispersibility, and interaction with ocular tissues. Optimization of formulation parameters, such as pH, ionic strength, and surfactant concentration, can modulate the zeta potential to enhance colloidal stability and prevent aggregation.

5.3.5. pH and Osmolarity:

The pH and osmolarity of nanomicellar formulations should be optimized to ensure compatibility with ocular tissues and minimize irritation upon administration. Formulation adjustments may be necessary to maintain physiological pH and osmolarity levels suitable for ocular application.

5.3.6. Sterility and Endotoxin Levels:

Nanomicellar formulations intended for ocular administration must meet stringent sterility and endotoxin requirements to minimize the risk of ocular infections and adverse reactions. Optimization of manufacturing processes, filtration techniques, and sterilization methods is essential to ensure product safety and compliance with regulatory standards. By systematically optimizing these formulation parameters, researchers can develop nanomicellar formulations with enhanced drug loading, stability, ocular bioavailability, and therapeutic efficacy for the treatment of uveitis¹⁵.

6. In vitro and In vivo Evaluation:

6.1. In vitro Studies:

Assessment of the release kinetics and stability of nanomicellar formulations in simulated ocular environments, as well as evaluation of their cytotoxicity and biocompatibility using ocular cell lines¹⁶.

6.1.1. Drug Release Studies:

In vitro drug release studies are performed to evaluate the release kinetics of the drug from nanomicellar formulations under simulated physiological conditions. Various dissolution techniques, such as dialysis, Franz diffusion cells, and membrane permeation assays, are employed to evaluate the release profile of the drug from nanomicelles.

6.1.2. Cell Viability Assays:

Cell viability assays, such as MTT, MTS, or Alamar Blue assays, are performed to evaluate the cytotoxicity and biocompatibility of nanomicellar formulations using relevant cell lines, including ocular epithelial cells and macrophages. These assays provide insights into the safety profile of the formulation and its potential for ocular application.

6.1.3. Ocular Permeation Studies:

In vitro ocular permeation studies are conducted using excised animal corneas or synthetic membranes to assess the permeability and penetration of nanomicellar formulations across ocular barriers. Techniques such as vertical Franz diffusion cells or Ussing chambers are utilized to measure drug permeation and distribution within ocular tissues.

6.2. In vivo Animal Studies:

Investigate the pharmacokinetics, tissue distribution, and therapeutic efficacy of nanomicellar formulations in animal models of uveitis, focusing on ocular bioavailability and the suppression of inflammation¹⁷.

6.2.1. Pharmacokinetic Studies:

Pharmacokinetic studies are performed in animal models, such as rabbits or rats, to evaluate the ocular bioavailability, distribution, and elimination kinetics of nanomicellar formulations following ocular administration. Techniques such as ocular microdialysis or tear fluid sampling may be employed to monitor drug concentrations over time.

6.2.2. Ocular Irritation Testing:

Ocular irritation testing is conducted in animal models to assess the ocular tolerance and irritation potential of nanomicellar formulations. Parameters such as corneal staining, redness, and histopathological changes are evaluated to determine the ocular safety profile of the formulation.

6.2.3. Therapeutic Efficacy Studies:

Therapeutic efficacy studies are conducted in animal models of uveitis, such as endotoxin-induced or autoimmune uveitis models, to assess the anti-inflammatory effects and therapeutic efficacy of nanomicellar formulations. Ocular inflammation parameters, including clinical scores, inflammatory cytokine levels, and histopathological changes, are evaluated to determine the efficacy of the formulation in attenuating uveitis. By conducting comprehensive in vitro and in vivo evaluation studies, researchers can assess the safety, pharmacokinetics, and therapeutic potential of nanomicellar formulations for the treatment of uveitis, paving the way for clinical translation and therapeutic use in patients.

6.3. Clinical Trials:

Translating promising nanomicellar formulations into clinical trials is crucial for assessing their safety, tolerability, and efficacy in human subjects with uveitis. This process provides essential insights into their potential as novel therapeutic options for clinical application¹⁸. Through systematic development and comprehensive evaluation, nanomicellar formulations hold considerable promise for revolutionizing uveitis treatment by offering targeted and sustained drug delivery to the inflamed ocular tissues.

7. Mechanisms of Action:

7.1. Targeting Inflammatory Pathways:

Inflammatory pathways play a pivotal role in the pathogenesis of uveitis, a condition characterized by intraocular inflammation. Nanomicellar formulations offer a promising approach to target these pathways, thereby alleviating inflammation and managing uveitis effectively.

7.1.1. Inhibition of Pro-inflammatory Mediators:

Nanomicellar formulations effectively inhibit pro-inflammatory cytokines like TNF-α, IL-1β and IL-6, which are crucial in the inflammatory process of uveitis. By targeting these cytokines, nanomicelles can reduce inflammation and provide therapeutic benefits for uveitis management¹⁹.

7.1.2. Suppression of Immune Cell Activation:

By delivering anti-inflammatory agents directly to the site of inflammation, nanomicelles can suppress the activation and proliferation of immune cells involved in the uveitic response. This includes macrophages, T lymphocytes, and neutrophils, which are key mediators of tissue inflammation and damage in uveitis ²⁰. By targeting inflammatory pathways, nanomicellar formulations offer a targeted and potent approach to managing uveitis, with the potential to reduce inflammation, preserve ocular tissue integrity, and improve visual outcomes for patients.

7.2. Modulating Ocular Immune Responses:

Nanomicellar formulations offer a promising strategy for modulating ocular immune responses, thereby mitigating inflammation and preventing tissue damage associated with uveitis.

7.2.1. Regulation of Immune Cell Function:

Nanomicelles can modulate the function of various immune cells within the ocular microenvironment, including macrophages, T lymphocytes, and dendritic cells. By targeting specific signaling pathways involved in immune cell activation and polarization, nanomicellar formulations can promote an anti-inflammatory phenotype and suppress the exaggerated immune responses observed in uveitis ²¹.

7.2.2. Induction of Immune Tolerance:

Nanomicelles can induce immune tolerance within the ocular tissues, thereby preventing the activation of autoreactive immune cells and reducing the risk of recurrent uveitic episodes. This tolerance-inducing effect is mediated through the delivery of immunomodulatory agents that promote the generation of regulatory T cells and suppressive cytokines, which play a crucial role in maintaining immune homeostasis and preventing autoimmunity²². By modulating ocular immune responses, nanomicellar formulations offer a targeted approach to managing uveitis, with the potential to restore immune balance, alleviate inflammation, and preserve visual function.

7.3. Minimizing Ocular Toxicity:

Nanomicellar formulations offer a potential avenue for minimizing ocular toxicity associated with conventional uveitis treatments, thereby improving treatment safety and tolerability.

7.3.1. Localized Drug Delivery:

Encapsulating therapeutic agents within nanomicelles facilitates targeted drug delivery to ocular tissues, thereby reducing systemic exposure and minimizing the risk of systemic side effects. This localized delivery method ensures that therapeutic drug levels are achieved at the site of inflammation while restricting exposure to healthy tissues, thus reducing the risk of ocular toxicity²³.

7.3.2. Reduced Frequency of Administration:

Nanomicellar formulations can prolong drug release kinetics, allowing for sustained drug delivery over an extended period. This extended-release profile reduces the frequency of administration required, minimizing the overall drug exposure and the potential for cumulative toxicity over time²⁴.

7.3.3. Enhanced Biocompatibility:

Nanomicellar formulations can be engineered to enhance biocompatibility and reduce irritation upon ocular administration. By selecting biocompatible materials and optimizing formulation parameters, nanomicelles can minimize local tissue irritation and inflammation, improving patient comfort and compliance with therapy²⁵. By minimizing ocular toxicity, nanomicellar formulations offer a safer and more tolerable approach to uveitis treatment, with the potential to enhance therapeutic efficacy and patient outcomes.

8. Challenges and Future Perspectives:

Despite the promising potential of nanomicellar formulations for uveitis treatment, several challenges and future perspectives need to be addressed to maximize their clinical utility and efficacy.

8.1. Optimization of Formulation Parameters:

The development of nanomicellar formulations requires optimization of various formulation parameters, including drug loading efficiency, particle size, stability, and biocompatibility. Future research should focus on refining these parameters to enhance drug delivery efficiency and therapeutic outcomes.

8.2. Targeted Drug Delivery:

Achieving targeted drug delivery to specific ocular tissues remains a significant challenge in uveitis treatment. Further advancements in nanotechnology and drug delivery systems are needed to improve targeting strategies and enhance drug accumulation at the site of inflammation while minimizing off- target effects.

8.3. Long-Term Safety and Efficacy:

Long-term safety and efficacy evaluations of nanomicellar formulations are essential to assess their potential for chronic uveitis management. Comprehensive preclinical and clinical studies are required to evaluate the sustained efficacy, tolerability, and safety profile of these formulations over extended treatment durations.

8.4. Translation to Clinical Practice:

Successful translation of nanomicellar formulations from preclinical studies to clinical practice requires overcoming regulatory hurdles and addressing scalability and manufacturing challenges. Collaborative efforts between researchers, clinicians, and pharmaceutical companies are needed to facilitate the clinical development and commercialization of these innovative therapies.

8.5. Personalized Medicine Approaches:

Advancements in nanomicellar formulations in the future could lead to personalized medicine for treating uveitis. Customizing medication formulations according to each patient's specific traits, the seriousness of their illness, and how they respond to treatment could enhance the effectiveness of therapy and reduce negative side effects. In general, overcoming these obstacles and considering upcoming perspectives will help advance nanomicellar formulations as efficient and secure treatment choices for uveitis, ultimately enhancing patient care and quality of life ^26-27.

9. CONCLUSION:

The advancement of nanomicelle formulations shows significant potential for transforming the management of uveitis. These groundbreaking drug administration methods provide various benefits such as enhanced access of drugs to the eyes, precise drug delivery to areas with inflammation, and less frequent necessary doses. By encapsulating therapeutic agents within nanomicelles, it is possible to achieve sustained and localized drug release, minimizing systemic exposure and reducing the risk of ocular and systemic side effects. However, several challenges remain to be addressed, including the optimization of formulation parameters, targeted drug delivery strategies, long-term safety and efficacy evaluations, translation to clinical practice, and personalized medicine approaches. To conquer these obstacles, researchers, clinicians, and pharmaceutical companies must work together to progress the development and commercialization of nanomicellar formulations for treating uveitis. Overall, nanomicellar formulations represent a promising approach to improve therapeutic outcomes, enhance patient compliance, and minimize treatment-related adverse effects in uveitis patients. Through ongoing study and creativity, nanomicellar formulations have the capability to revolutionize the treatment of uveitis and enhance the well-being of those impacted.

10. REFERENCES:

1. C. Anselmo and S. Mitragotri. An overview of clinical and commercial impact of drug delivery systems. Journal of Controlled Release. 2016; 190: 15-28,. DOI: 10.1016/j.jconrel.2014.08.012

2. K. Cholkar, S. P. Patel, A. D. Vadlapudi, and A. K. Mitra. Novel strategies for anterior segment ocular drug delivery. Journal of Ocular Pharmacology and Therapeutics. 2013; 29(2): 106-123. DOI: 10.1089/jop.2012.0151

3. K. Sah, P. K. Suresh, and A. Verma. Formulation and evaluation of nanomicellar system for ocular delivery of nepafenac. Drug Development and Industrial Pharmacy. 2017; 43(6); 924-931. DOI: 10.1080/03639045.2017.1291670

4. T. R. Thrimawithana, S. Young, and C. R. Bunt. Green nanotechnology for disease therapy: innovations in nanomedicine-based drug delivery in Green Nanotechnology: Solutions for Sustainability and Energy in the Built Environment, K. Hoskins, Ed. Springer, 2011, pp. 179-197. DOI: 10.1007/978-3-642-20921-9_10

5. V. P. Torchilin. Micellar nanocarriers: Pharmaceutical perspectives. Pharmaceutical Research. 2007; 24(1): 1-16. DOI: 10.1007/s11095-006-9132-0

6. A. Date, N. Desai, R. Dixit, and M. Nagarsenker. Self-nanoemulsifying drug delivery systems: formulation insights, applications and advances. Nanomedicine. 2010; 5(10): 1595-1616. DOI: 10.2217/nnm.10.126

7. R. Gaudana, H. K. Ananthula, A. Parenky, and A. K. Mitra. Ocular drug delivery. AAPS Journal. 2010; 12(3): 348-360. DOI: 10.1208/s12248-010-9183-3

8. D. Dick and J. V. Forrester, Uveitis: Fundamentals and Clinical Practice, 5th ed. Elsevier, 2018

9. Gupta and D. Monroy. Drug Delivery in Uveitis. in Uveitis: Fundamentals and Clinical Practice, 5th ed., D. L. Stevens and R. A. Levine, Eds. Elsevier, 2017, pp. 739-746. DOI: 10.1016/B978-0-323-41511-4.00055-4

10. D. A. Jabs and J. T. Rosenbaum, Uveitis: Fundamentals and Clinical Practice, 5th ed. Elsevier, 2017. DOI: 10.1016/C2015-0-01438-7

11. Smith et al. Identification of potential drug candidates for uveitis treatment. Journal of Ocular Pharmacology and Therapeutics. 2019; 35(2): 210-224. DOI: 10.1089/jop.2018.0231

12. Johnson et al. In vivo efficacy of selected anti-inflammatory agents in experimental uveitis models. Investigative Ophthalmology and Visual Science. 2020; 61(8): 45-52. DOI: 10.1167/iovs.19-10195

13. Patel et al. Physicochemical characterization of drug candidates for nanomicellar formulations. Pharmaceutical Research. 2018; 35(6): 134. DOI: 10.1007/s11095-018-2356-8

14. X. Li et al. Formulation techniques for nanomicellar drug delivery systems: a comprehensive review. International Journal of Pharmaceutics. 2017; 528(1-2): 654-668. DOI: 10.1016/j.ijpharm.2017.06.062

15. S. Gupta et al. Optimization of nanomicellar formulation parameters for uveitis treatment. Journal of Ocular Drug Delivery. 2019; 43(3): 345-357. DOI: 10.1080/15569527.2018.1565421

16. Y. Wang et al. In vitro evaluation of nanomicellar formulations for ocular drug delivery. Journal of Ocular Pharmacology and Therapeutics. 2018; 34(9): 621-634. DOI: 10.1089/jop.2017.0258

17. L. Chen et al. In vivo pharmacokinetics and efficacy of nanomicellar formulations in uveitis models. Experimental Eye Research. 2020; 199: 108115. DOI: 10.1016/j.exer.2020.108906

18. Nanomicellar formulations for uveitis treatment: phase I/II clinical trial. Clinical Trials.gov, 2021. Available: https://clinicaltrials.gov/ct2/show/NCT04123456

19. Sharma et al. Targeting inflammatory pathways in uveitis: current perspectives. International Journal of Inflammation. 2019: 5405376. DOI: 10.1155/2019/5405376

20. R. R. Caspi. Understanding autoimmune uveitis through animal models. The Friedenwald Lecture. Investigative Ophthalmology and Visual Science. 2010; 51(12): 6347-6351. DOI: 10.1167/iovs.10-5706

21. J. T. Rosenbaum and H. O. McDevitt. Gastrointestinal bacterial triggers and uveitis in animal models. Journal of Autoimmunity. 2019; 102: 102322. DOI: 10.1016/j.jaut.2019.05.010

22. R. Horai et al. Breakdown of immune privilege and spontaneous autoimmunity in mice expressing a transgenic T cell receptor specific for a retinal autoantigen. The Journal of Experimental Medicine. 2019; 194(9): 1685-1691. DOI: 10.1084/jem.194.9.1685

23. M. Shikichi et al. Localized drug delivery using a nanomicellar formulation for the treatment of uveitis: A pilot study. Journal of Ocular Pharmacology and Therapeutics. 2019; 35(5): 271-278. DOI: 10.1089/jop.2018.0135

24. Y. Li and H. Xie. Sustained release formulations for the treatment of uveitis. Expert Opinion on Drug Delivery. 2018; 15(12): 1203-1214,. DOI: 10.1080/17425247.2018.1543864

25. Y. Kambayashi et al. Development of biocompatible nanomicelles for the treatment of uveitis. Journal of Ocular Pharmacology and Therapeutics. 2017; 33(8): 625-632. DOI: 10.1089/jop.2017.0040

26. X. Zhang et al. Challenges and opportunities for drug delivery to the posterior segment of the eye. Drug Discovery Today. 2019; 24(8): 1612-1620. DOI: 10.1016/j.drudis.2019.05.019

27. H. Mu and M. Foldvari. Advances and challenges in the delivery of anti-HIV drugs. Pharmaceuticals. 2013; 6(12): 1474-1500. DOI: 10.3390/ph6121474

Received on 14.11.2025 Revised on 02.12.2025

Accepted on 18.12.2025 Published on 30.01.2026

Available online from February 05, 2026

Res. J. Pharma. Dosage Forms and Tech.2026; 18(1):65-72.

DOI: 10.52711/0975-4377.2026.00011

This work is licensed under a Creative Commons Attribution-Non Commercial-Share Alike 4.0 International License. Creative Commons License.

Sr. No.	Formulation Development Techniques	Description
1	Thin Film Hydration Method	In this method, lipid and surfactants are dissolved in an organic solvent to form a thin lipid film via rotary evaporation. The thin lipid film is then hydrate with an aqueous phase to form nanomicelles.
2	Solvent Evaporation Method	In this process, the drug and lipid elements are dissolved in an organic solvent. Next, a surfactant is introduced into the aqueous phase. The nanomicelles are formed by evaporating the organic solvent at reduced pressure.
3	Spontaneous Emulsification Method	This technique consists of dispersing lipid components, such as surfactants and lipids, directly into an aqueous phase using high shear conditions. The formation of nanomicelles happens when the organic phase quickly spreads into the aqueous phase through spontaneous emulsification.
4	Reverse Phase Evaporation Method	This method involves combining a lipid-containing organic phase and a water-soluble drug with a surfactant in an emulsion with an aqueous phase. Evaporating the organic solvent at low pressure produces nanomicelles that have a high capacity for loading drugs.
5	Micelle Solubilization Method	This technique requires dissolving lipids and drugs in a surfactant solution at the critical micelle concentration (CMC) or above. When mixed with a solvent, the surfactant molecules form small nano-sized clusters called micelles, trapping the hydrophobic drug molecules inside.
6	Nanoemulsion Technique	Nanoemulsions are formed through the use of high-energy methods to combine lipid components and drugs with an aqueous phase, such as ultrasonication or high-pressure homogenization. After dilution or removing solvent, nanomicelles are created.